A randomised, double-blind, multicentre phase ii trial to evaluate the biological effects, safety and pharmacokinetics of single agent zd1839 (iressatm) and zd1839 in combination with anastrozole (arimidex®) in patients with primary breast cancer

Trial Profile

A randomised, double-blind, multicentre phase ii trial to evaluate the biological effects, safety and pharmacokinetics of single agent zd1839 (iressatm) and zd1839 in combination with anastrozole (arimidex®) in patients with primary breast cancer

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs Gefitinib (Primary) ; Anastrozole
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms Coombes Study 77
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top